Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
| dc.contributor.author | Sezer, Ahmet | |
| dc.date.accessioned | 2022-08-03T08:51:37Z | |
| dc.date.available | 2022-08-03T08:51:37Z | |
| dc.date.issued | 2021 | |
| dc.identifier.issn | 0732-183X | en_US |
| dc.identifier.uri | http://hdl.handle.net/11727/7205 | |
| dc.language.iso | eng | en_US |
| dc.relation.isversionof | 10.1200/JCO.2021.39.15_suppl.9085 | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis. | en_US |
| dc.type | conferenceObject | en_US |
| dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | en_US |
| dc.identifier.volume | 39 | en_US |
| dc.identifier.issue | 15 | en_US |
| dc.identifier.wos | 000708120605064 | en_US |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
